Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM · NASDAQ Global Market
+$3.42 today
Vol 1.46M · Avg 0.81M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$196.5M +24.6% | -$260.6M -41.1% | -$184.7M -2.0% | -$181.1M -160.2% | -$69.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $1.3M -14.4% | $1.6M -11.1% | $1.8M +5.1% | $1.7M +44.4% | $1.2M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 +100.0% | -$100.0M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $66.8M +68.4% | $39.7M +21.9% | $32.6M +64.2% | $19.8M -4.7% | $20.8M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$968.0K -109.2% | $10.6M +120.0% | $4.8M +124.4% | -$19.7M -1139.7% | $1.9M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$7.6M -107.7% | -$3.6M +57.8% | -$8.6M -66.2% | -$5.2M -315.9% | -$1.3M | $592.6M | $1.3B | $626.2M |
| Inventory | -$7.5M +26.1% | -$10.1M -77.3% | -$5.7M -103.4% | -$2.8M -25409.1% | -$11.0K | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $21.9M -0.1% | $21.9M +48.4% | $14.8M +857.4% | $1.5M -91.6% | $18.3M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$7.8M -423.1% | $2.4M -44.8% | $4.4M +133.1% | -$13.3M +12.5% | -$15.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $13.7M -85.6% | $94.9M +909.3% | $9.4M +59.0% | $5.9M +2464.8% | -$250.0K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$115.7M -1.6% | -$113.9M +16.4% | -$136.2M +21.5% | -$173.4M -18.8% | -$146.0M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$953.0K | $0 +100.0% | -$47.0K +98.9% | -$4.3M +21.2% | -$5.4M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 -100.0% | $4.0M -96.0% | $100.0M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$348.7M -29.9% | -$268.3M +24.4% | -$354.9M -40.9% | -$251.9M +52.0% | -$525.0M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $252.5M -3.1% | $260.6M -26.6% | $355.0M +24.9% | $284.2M -21.3% | $361.2M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$40.0M +1.2% | -$40.5M -614.7% | -$5.7M -41.7% | -$4.0M -157.1% | $7.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$137.2M -184.7% | -$48.2M -750.4% | -$5.7M -120.2% | $28.0M +145.1% | -$62.2M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 +100.0% | -$12.9M | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $237.9M +21.8% | $195.2M +299.5% | $48.9M -62.7% | $131.1M -18.9% | $161.7M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 +100.0% | -$4.0M | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$19.9M -254.8% | $12.9M -49.5% | $25.5M -69.2% | $82.7M +1639.6% | $4.8M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $218.0M +14.0% | $191.2M +157.2% | $74.4M -65.2% | $213.8M +28.4% | $166.5M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $87.0K +4250.0% | $2.0K +101.4% | -$142.0K | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$34.8M -219.1% | $29.2M +143.2% | -$67.6M -198.8% | $68.4M +264.2% | -$41.7M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$116.6M -2.4% | -$113.9M +16.4% | -$136.2M +23.4% | -$177.7M -17.3% | -$151.4M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$34.50B
Nuvalent, Inc.
NASDAQ:NUVL
$9.08B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.31B
Arcellx, Inc.
ACLX
$6.73B
Akero Therapeutics, Inc.
AKRO
$4.50B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$4.16B
uniQure N.V.
NASDAQ:QURE
$2.98B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.83B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.94B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.77B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.53B
Ventyx Biosciences, Inc.
VTYX
$1.00B
MeiraGTx Holdings plc
NASDAQ:MGTX
$1.00B
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$917.57M
Solid Biosciences Inc.
NASDAQ:SLDB
$599.52M
Arvinas, Inc.
NASDAQ:ARVN
$508.43M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$366.34M
Inozyme Pharma, Inc.
INZY
$258.25M
Atrium Therapeutics, Inc.
NASDAQ:RNA
$218.04M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
$98.62M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$72.45M
SEC Filings
Recent regulatory filings
No filings found.
Does RYTM generate free cash flow?
Rhythm Pharmaceuticals, Inc. (RYTM) generated -$116,628,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does RYTM produce?
Operating cash flow was -$115,675,000.00, before capital expenditures of $953,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.